Kymera Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.Some support4 reports2 developments inside
-
Kymera Therapeutics listed on the stock exchange and filed required disclosures with the SEC on June 22, 2026.Some support2 reports
-
Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.Some support3 reports
-
Sanofi will advance Kymera Therapeutics into clinical testing.Speculative1 report
-
Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.Speculative2 reports
-
Kymera Therapeutics was recognized as one of Boston’s top workplaces.Some support2 reports
-
Kymera Therapeutics appointed Brian Adams as Chief Legal Officer and announced the retirement of Ellen Chiniara.Some support1 report
-
Kymera Therapeutics listed its stock on the Nasdaq exchange on May 27, 2026.Well supported8 reports
No events began in the chosen period. Widen it, or reset.
Around Kymera Therapeutics this week
News at the entities that move Kymera Therapeutics most-
Gilead Sciences OperationalGilead Sciences licensed a drug to manufacturers in India on November 14, 2026.Moves Kymera Therapeutics
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Kymera Therapeutics
-
Food and Drug Administration StructuralSeaStar Medical submitted a premarket approval application to the FDA and discussed trial enrollment plans.Moves Kymera Therapeutics
-
Morgan Stanley TransactionalMorgan Stanley and JPMorgan Chase issued similar preferred dividend declarations on November 1, 2026.Moves Kymera Therapeutics
-
Nasdaq StructuralWindward Bio successfully listed on the Nasdaq exchange and is a portfolio company of Qiming Venture Partners.Moves Kymera Therapeutics
-
Leerink partners TransactionalLeerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.Moves Kymera Therapeutics
Connections
The 15 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Gilead Sciences Operational
Kymera Therapeutics and Gilead Sciences have entered an exclusive license agreement to co-develop and commercialize molecular glue degraders for cancer.
-
Sanofi Structural
Kymera and Sanofi maintain a formal, ongoing partnership where Sanofi advances Kymera's drug candidates into clinical testing.
-
Nasdaq Structural
Kymera Therapeutics is formally listed and trades on the Nasdaq stock exchange.
-
SEC Structural
Kymera Therapeutics is subject to mandatory regulatory oversight and filing requirements by the SEC.
-
Food and Drug Administration Structural
Kymera Therapeutics is subject to formal regulatory oversight and alignment requirements from the Food and Drug Administration for clinical trials.
-
Noah Goodman Transactional
Noah Goodman, identified as an insider, sold shares of Kymera Therapeutics stock.
-
Morgan Stanley Transactional
Morgan Stanley provided investment banking services, including stock upgrades and book-running, for Kymera Therapeutics.
-
Leerink partners Transactional
Leerink Partners served as a joint book-running manager for Kymera Therapeutics.
Show all 15 connections
-
Gilead Operational
Kymera Therapeutics and Gilead are engaged in active collaborations and partnership deals for drug development.
-
Citigroup Mentioned together
Citigroup published a buy rating and price targets for Kymera Therapeutics.
-
Sanofi Operational
Kymera Therapeutics is actively competing with Sanofi for market position in the pharmaceutical sector.
-
Edward Nash Mentioned together
Edward Nash, an analyst, raised a price target on Kymera Therapeutics stock.
-
Boston Shared context
Kymera Therapeutics is located in Boston and is described as a local drug developer.
-
Wave Life Sciences Mentioned together
Financial activity involving secondary offerings and insider buying was observed.
-
Brian Adams Transactional
Brian Adams, identified as an insider, sold 6,371 shares of Kymera Therapeutics stock on September 4, 2026.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
1 eventJune 2026
9 events- Sanofi advances Kymera's degrader candidate.
- Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.
- Kymera Therapeutics listed on the stock exchange and filed required disclosures with the SEC on June 22, 2026.
- Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.
- Sanofi will advance Kymera Therapeutics into clinical testing.
- Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.
- Kymera Therapeutics was recognized as one of Boston’s top workplaces.
- Kymera Therapeutics appointed Brian Adams as Chief Legal Officer and announced the retirement of Ellen Chiniara.
- Kymera Therapeutics listed its stock on the Nasdaq exchange on May 27, 2026.